Skip to content

Study · Randomized controlled trial · n = 26 · 2017

5 results

Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes.

Garg M, Ghanim H, Kuhadiya ND, Green K, Hejna J, Abuaysheh S, Torre B, Batra M, Makdissi A, Chaudhuri A, Dandona P

Diabetes, obesity & metabolism18 May 2017Cited by 23 (Europe PMC)

PMID28304146 (opens in a new tab)DOI10.1111/dom.12944 (opens in a new tab)PepBankPUB-28304146
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with inadequately controlled type 1 diabetes, a single dose of liraglutide 1.8 mg significantly reduced the rise in free fatty acids versus placebo.

    In plain wordsIn adults with type 1 diabetes, one dose of liraglutide reduced the rise in blood fatty acids compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseRise in free fatty acids
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 5 hoursAs given in this study (human).

    Source sentences

    Summary
    liraglutide significantly reduced the increase in FFA, and totally prevented the increase in acetoacetate and β-hydroxybutyrate concentrations while suppressing glucagon and ghrelin concentrations.
    3 context sentences
    Summary · context
    Twenty-six patients with inadequately controlled T1DM were randomly divided into 2 groups of 13 patients each.
    Summary · context
    After an overnight fast, patients were injected, subcutaneously, with either liraglutide 1.8 mg or with placebo.
    Summary · context
    They were maintained on their basal insulin infusion and were followed up in our clinical research unit for 5 hours.
  2. 02HumanRandomized controlled trialMechanism

    In adults with inadequately controlled type 1 diabetes, a single dose of liraglutide 1.8 mg totally prevented the rise in acetoacetate seen with placebo.

    In plain wordsIn adults with type 1 diabetes, one dose of liraglutide prevented the rise in the ketone acetoacetate seen with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseRise in acetoacetate
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 5 hoursAs given in this study (human).

    Source sentences

    Summary
    totally prevented the increase in acetoacetate and β-hydroxybutyrate concentrations
    4 context sentences
    Summary · context
    The patients injected with placebo maintained their glucose and glucagon concentrations without an increase, but there was a significant increase in free fatty acids (FFA), acetoacetate and β-hydoxybutyrate concentrations.
    Summary · context
    Twenty-six patients with inadequately controlled T1DM were randomly divided into 2 groups of 13 patients each.
    Summary · context
    After an overnight fast, patients were injected, subcutaneously, with either liraglutide 1.8 mg or with placebo.
    Summary · context
    They were maintained on their basal insulin infusion and were followed up in our clinical research unit for 5 hours.
  3. 03HumanRandomized controlled trialMechanism

    In adults with inadequately controlled type 1 diabetes, a single dose of liraglutide 1.8 mg totally prevented the rise in beta-hydroxybutyrate seen with placebo.

    In plain wordsIn adults with type 1 diabetes, one dose of liraglutide prevented the rise in the ketone beta-hydroxybutyrate seen with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseRise in beta-hydroxybutyrate
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Fat metabolism and adipogenesis · Metabolic and weight
    Studied dose
    1.8 mg · subcutaneous · 5 hoursAs given in this study (human).

    Source sentences

    Summary
    In contrast, liraglutide significantly reduced the increase in FFA, and totally prevented the increase in acetoacetate and β-hydroxybutyrate concentrations while suppressing glucagon and ghrelin concentrations.
    3 context sentences
    Summary · context
    Twenty-six patients with inadequately controlled T1DM were randomly divided into 2 groups of 13 patients each.
    Summary · context
    After an overnight fast, patients were injected, subcutaneously, with either liraglutide 1.8 mg or with placebo.
    Summary · context
    They were maintained on their basal insulin infusion and were followed up in our clinical research unit for 5 hours.
  4. 04HumanRandomized controlled trialMechanism

    In adults with inadequately controlled type 1 diabetes, a single dose of liraglutide 1.8 mg suppressed glucagon concentrations.

    In plain wordsIn adults with type 1 diabetes, one dose of liraglutide lowered glucagon levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseGlucagon concentration
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.8 mg · subcutaneous · 5 hoursAs given in this study (human).

    Source sentences

    Summary
    In contrast, liraglutide significantly reduced the increase in FFA, and totally prevented the increase in acetoacetate and β-hydroxybutyrate concentrations while suppressing glucagon and ghrelin concentrations.
    3 context sentences
    Summary · context
    Twenty-six patients with inadequately controlled T1DM were randomly divided into 2 groups of 13 patients each.
    Summary · context
    After an overnight fast, patients were injected, subcutaneously, with either liraglutide 1.8 mg or with placebo.
    Summary · context
    They were maintained on their basal insulin infusion and were followed up in our clinical research unit for 5 hours.
  5. 05HumanRandomized controlled trialMechanism

    In adults with inadequately controlled type 1 diabetes, a single dose of liraglutide 1.8 mg suppressed ghrelin concentrations.

    In plain wordsIn adults with type 1 diabetes, one dose of liraglutide lowered ghrelin levels.

    Peptide
    Liraglutide
    Outcome
    DecreaseGhrelin concentration
    Study

    n = 26

    Comparator
    Placebo
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    1.8 mg · subcutaneous · 5 hoursAs given in this study (human).

    Source sentences

    Summary
    In contrast, liraglutide significantly reduced the increase in FFA, and totally prevented the increase in acetoacetate and β-hydroxybutyrate concentrations while suppressing glucagon and ghrelin concentrations.
    3 context sentences
    Summary · context
    Twenty-six patients with inadequately controlled T1DM were randomly divided into 2 groups of 13 patients each.
    Summary · context
    After an overnight fast, patients were injected, subcutaneously, with either liraglutide 1.8 mg or with placebo.
    Summary · context
    They were maintained on their basal insulin infusion and were followed up in our clinical research unit for 5 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.